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Adverse events profile of oral
corticosteroids among asthma patients in
the UK: cohort study with a nested case-
control analysis
Marlene Bloechliger1,2,7, Daphne Reinau1,2, Julia Spoendlin1,2, Shih-Chen Chang3, Klaus Kuhlbusch4,
Liam G. Heaney5, Susan S. Jick6 and Christoph R. Meier1,2,6*
Abstract
Background: To evaluate the adverse events profile of oral prednisolone among adult asthma patients in the UK.
Methods: Using data from the UK-based Clinical Practice Research Datalink, we conducted a series of cohort studies to
quantify incidence rates and incidence rate ratios, and a series of nested case-control analyses to estimate crude and
adjusted odds ratios, of 11 different potential corticosteroid-related adverse events (bone-related conditions, hypertension,
peptic ulcer, severe infections, herpes zoster, diabetes mellitus type 2, cataract, glaucoma, chronic kidney disease, affective
disorders, and cardiovascular events).
Results: Between 165,900 and 269,368 asthma patients were included in each of the 11 cohorts, of whom between 836
and 16,192 developed an outcome of interest. Incidence rates per 1000 person-years of potential corticosteroid-related
adverse events in patients with new current use of oral prednisolone ranged from 1.4 (95% confidence interval [CI],
1.0–1.8) for peptic ulcer to 78.0 (95% CI, 74.8–81.2) for severe infections. After adjusting for confounding, current oral
prednisolone use was most strongly associated with an increased risk of severe infection, compared with non-use of
prednisolone; OR 2.16 (95% CI, 2.05–2.27). There were smaller elevated risks of peptic ulcer, affective disorders, and
cataract at higher doses, and marginally increased risks of herpes zoster, cardiovascular events, diabetes mellitus type
2, and bone related conditions, compared with non-use of prednisolone. We did not observe an association between
oral prednisolone use and glaucoma, chronic kidney disease, or hypertension.
Conclusion: Oral prednisolone use is associated with infections, gastrointestinal, neuropsychiatric, ocular,
cardiovascular, metabolic, and bone-related complications among adult asthma patients.
Keywords: Clinical practice research datalink, Asthma, Corticosteroids, Adverse events, Observational study
Background
Asthma is among the most common chronic diseases
worldwide and poses a substantial public health burden
[1, 2]. In the United Kingdom (UK), one in 12 adults re-
quires asthma treatment, and the disease accounts for
more than 1000 deaths a year [3].
The Global Initiative for Asthma (GINA) and the British
Thoracic Society/Scottish Intercollegiate Guidelines Net-
work (BTS/SIGN) guidelines for asthma management in-
clude a stepwise treatment approach based on use of
inhaled corticosteroids (ICS) with or without inhaled
long-acting beta-adrenoceptor agonists (LABA) [4, 5]. For
patients with severe asthma not controlled by ICS and
LABA, guidelines include low-dose oral corticosteroids
(OCS) as add-on treatment to mitigate inflammation, re-
lieve symptoms, and prevent exacerbations.
OCS use has been linked to a variety of adverse events
including osteoporosis and subsequent bone fractures,
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peptic ulcer, susceptibility to infections, hyperglycaemia,
hypertension, ocular complications, cardiovascular events,
and neuropsychiatric disorders [6–9]. Two recently con-
ducted cross-sectional studies among asthma patients
based on United States (US) commercial claims data and
data from UK primary and secondary care databases,
respectively, suggested relevant associations between
frequent OCS use and various potential corticosteroid-
related adverse events [10, 11]. However, the temporal re-
lationship between these disorders and OCS exposure
could not be established. Three retrospective cohort
studies based on different US claims databases also docu-
mented a potentially increased risk for corticosteroid-
related diseases in asthma patients who used systemic
corticosteroids compared with non-users; additionally, the
risk increased with increasing daily OCS dose [12–14].
Most of these studies restricted OCS exposed groups to
severe asthma patients with frequent OCS use [10, 11], or
with an initial period of continuous systemic corticoster-
oid use at high daily doses (≥5 mg prednisolone or equiva-
lent) [12, 13]. The most recently published cohort study
included asthma patients with different disease stages and
assessed the association between the frequency of OCS
prescriptions issued per year and various adverse out-
comes [14]. None of these studies investigated absolute
risk estimates of potentially corticosteroid-related adverse
events among asthma patients with or without OCS use.
In the present study, we examined the risk of OCS-
related adverse events in a large population of UK
patients enrolled in the well-validated Clinical Practice
Research Datalink (CPRD). We included patients with
different stages of asthma severity, reflecting a more
general asthma population compared to most previous
studies. In a series of cohort analyses we estimated crude
incidence rates of 11 potentially corticosteroid-related
adverse events in users and non-users of OCS. We
further conducted a series of case-control analyses
nested within these cohorts to assess in more depth the
association between timing, frequency, cumulative and
average daily doses of OCS use, and the occurrence of
these adverse events.
Methods
Study design and data source
We conducted a series of 11 cohort studies, each with a
nested case-control analysis, using data from the CPRD.
The CPRD is a large and well-validated UK-based
electronic primary care database with ongoing data col-
lection, which contains anonymised, longitudinal data
recorded by general practitioners (GPs) in daily clinical
practice. Available information includes demographics,
lifestyle factors, medical diagnoses, prescription history,
specialist referrals, hospitalisations, and laboratory test
results. The database encompasses approximately 10
million patient records from approximately 600 GP
practices throughout the UK. Patients are representative
of the UK population with regard to age, sex, and annual
turnover rate [15]. Numerous studies have demonstrated
the completeness and high validity of the recorded infor-
mation [16, 17].
This study was approved by the Independent Scientific
Advisory Committee for Medicines and Healthcare
Products Regulatory Agency research (protocol number
16_060R).
Study population
We identified all patients in the CPRD aged 18 years or
older with incident or prevalent asthma (defined as re-
quiring at least GINA step 2 treatment [4]) between
January 2000 and December 2015. A qualifying asthma
diagnosis was defined as a recorded Read code (clinical
coding system used in UK primary care) for asthma at
any time in the patient record, which was preceded and/
or followed by an ICS prescription within 90 days prior
or up to 365 days after. The date of cohort entry for
these patients was either 1 January 2000 (for those who
qualified before 1 January 2000, i.e. the prevalent asthma
patients) or the date of the qualifying ICS prescription,
whichever came last.
We excluded patients with (1.) < 3 years of recorded
history in the CPRD before cohort entry, to allow for
sufficient time to measure covariates (2.) a previous rec-
ord of malignancy (except non-melanoma skin cancer),
HIV/AIDS, alcoholism, or drug abuse, since these condi-
tions and/or the associated drug therapies can lead to
immune suppression and to a higher risk of several of
the outcomes assessed, (3.) previously recorded differen-
tial diagnoses of asthma and/or a disease that is associ-
ated with chronic OCS use (rheumatoid arthritis,
polymyalgia rheumatica, systemic lupus erythematosus,
vasculitis, multiple sclerosis, chronic obstructive pul-
monary disease, bronchiectasis, cystic fibrosis, interstitial
pulmonary fibrosis, tuberculosis, autoimmune hepatitis,
inflammatory bowel disease), (4.) ≥1 recorded OCS
prescription within 2 years, or ≥4 recorded OCS pre-
scriptions at any time, before cohort entry, to insure
new use of OCS, (5.) prevalent asthma who did not have
a recorded ICS prescription within 365 days before 1
January 2000, to ensure persisting asthma at cohort
entry, (6.) the recorded outcome of interest (Table 1)
prior to cohort entry.
Cohort analyses
Follow-up and definition of outcomes
We followed patients from the date of cohort entry until
the first record of an outcome of interest (Table 1),
death, loss to follow-up, the end of the study period (30
December 2015), a code indicating the onset of an
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exclusion criterion outlined above, or the day after a
period of 365 days without any recorded ICS prescrip-
tions (presumed asthma remission). Most patients were
included in all study cohorts, and right-censoring of
follow-up was different for each outcome. If patients
modified their prednisolone exposure as a consequence
of the occurrence of an outcome, this could have af-
fected the analyses of outcomes that occurred later on.
Person-time analyses and definition of exposure
We classified follow-up time for each patient into non-,
current, or past use of OCS (subsequently referred to as
oral prednisolone, since < 2% of the study population
received OCS other than prednisolone). We defined
non-use as the time period between cohort entry and
the first oral prednisolone prescription or the censoring
date, whichever came first. Current or past use was de-
fined by estimating the supply of each prescription based
on the total quantity of tablets prescribed and the dosage
instructions, according to an algorithm developed based
on a previous CPRD study [18] (see Additional file 1 for
details on the algorithm, a scheme of the cohort analysis,
and the extent of missing data on quantity of tablets or
dosing instructions in each cohort).
Nested case-control analyses
Definition of cases and controls
Cases were patients who had a first ever code for one of
the study outcomes during the study period. The date of
the recorded outcome will subsequently be referred to
as the index date. We identified up to 4 controls for
each case of the 11 study outcomes, from those in the
asthma study population who did not have the outcome
of interest prior to the case index date (risk set
sampling). We matched controls to cases on index date,
duration of follow-up (+/− 2 years), year of birth (+/−
2 years), sex, and duration of history in the database
(+/− 0 years).
Table 1 Definition of the outcomes of interest
Outcome Definition
Bone-related conditions Incident Read code of bone fracture (ankle, foot, toe, hand, finger, hip, femur, humerus,
shoulder, clavicle, scapula, lower arm, elbow, wrist, vertebra or unspecific fracture) or
osteoporosis.
Hypertension Incident Read code of hypertension preceded or followed within 180 days prior until
180 days after by a prescription for an antihypertensive drug (ACE inhibitor, ARB,
dihydropyridine CCB or thiazide diuretic).
The first record of either hypertension or antihypertensive treatment was assigned the
date of outcome occurrence.
Peptic ulcer Incident Read code of peptic ulcer with or without haemorrhage.
Severe infections Main analysis: incident Read code of an infection preceded or followed within 1 month
by a record suggesting hospitalisation or i.v. anti-infective treatment.
Sensitivity analysis restricted to patients with IHS linkage (conducted in the nested-case
control study only): incident Read code of an infection preceded or followed within
1 month by a hospitalisation whose reason was infection (ICD-10 code of infection in
the IHS data).
Herpes zoster Incident Read code of herpes zoster
DM2 Incident Read code of DM2 and/or a first-time prescription for an oral antidiabetic drug,
whichever came first.
If a patient was prescribed insulin before any other antidiabetic drug during follow-up
(and therefore likely was diagnosed with DM1), the event did not count as an outcome
and the person was censored at the date of the insulin prescription.
Cataract Incident Read code of cataract or a procedure for lens replacement, whichever came first.
Glaucoma Incident Read code of glaucoma or a first-time prescription for intraocular pressure-
lowering therapy, whichever came first.
CKD Incident Read code of CKD or ≥2 recorded values of an eGFR of < 60 ml/min/1.73m2
within 365 days and separated by ≥90 days (calculated based on the CKD-EPI equation).
Affective disorders Incident Read code of affective disorders (depression, bipolar affective disorder, manic
episodes) preceded or followed within 180 days before or after by a prescription for an
antidepressant or mood stabilizing drug, or a Read code indicating psychotherapy.
The first record of either affective disorders or the respective treatment was assigned the
date of outcome occurrence.
Cardiovascular events Incident Read code of myocardial infarction, ischaemic heart disease, or ischaemic stroke.
Abbreviations: ACE angiotensin-converting-enzyme, ARB angiotensin II receptor blocker, CCB calcium channel blocker, CKD chronic kidney disease, CKD-EPI Chronic
Kidney Disease Epidemiology Collaboration, DM1 diabetes mellitus type 1, DM2 diabetes mellitus type 2, eGFR estimated glomerular filtration rate, IHS integrated
hospital episode statistics, i.v. intravenous
Read codes: thesaurus of clinical terms
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Definition of exposure
We defined non-users as patients with no oral prednisol-
one prescriptions prior to the index date, and ever users
as patients with ≥1 oral prednisolone prescription
recorded at any time before the index date. We further
categorised ever users into current, recent, or past users,
when their last prescription was recorded < 180, 180–
365, or > 365 days before the index date, respectively.
We sub-classified current oral prednisolone users by (1.)
cumulative dose prescribed before the index date (<
500 mg, 500-2000 mg, > 2000 mg), and (2.) average daily
dose (≤1 mg, > 1 mg–5 mg, > 5 mg) ever, calculated based
on the cumulative dose prescribed ever, divided by the days
since the first prescription, and within periods of 1, 2, and
5 years before the index date, calculated based on the cu-
mulative dose prescribed within 1, 2, or 5 years before the
index date, divided by 365, 730, or 1825 days, respectively,
and (3.) frequency of prescriptions before the index date
(low use: on average 1 prescription/year; medium use: on
average 2–3 prescriptions per year; high use: on average ≥
4 prescriptions per year), was calculated based on the sum
of prescriptions and the time since the first prescription.
Definition of covariates
We assessed the following potential confounders at any
time before the index date of each case and control based
on a priori clinical knowledge: alcohol consumption (most
recent record before the index date: </≥14 units of alcohol
per week, or unknown); smoking status (most recent record
before the index date: non-, current-, ex-smoker, or
unknown); body mass index (most recent record before the
index date: < 18.5, 18.5–24.9, 25.0–29.9, ≥30.0, or un-
known); current or past use (yes/no) of inhaled bronchodi-
lators, nonsteroidal anti-inflammatory drugs, platelet
aggregation inhibitors, anticoagulants, proton pump
inhibitors, vitamin D/calcium, bisphosphonates, and immu-
nosuppressants; the number of ICS prescriptions (as a
continuous variable), and the Charlson Comorbidity Index
(a summary measure for disease burden of a patient [19]; as
a continuous variable, and categorized in 0, 1–3, 4–6, > 6).
Statistical analysis
Cohort analyses
We performed a series of 11 cohort studies to assess
crude incidence rates (IRs) with 95% confidence inter-
vals (CIs) for each outcome among non-users, ever users
(current and past users combined), and current users of
oral prednisolone. We compared IRs for ever- and
current users with those for non-users by calculating
crude incidence rate ratios (IRRs) with 95% CIs.
Nested case-control analyses
We conducted a series of 11 nested case-control
analyses for each outcome of interest to assess in more
detail the association between oral prednisolone use and
the identified adverse events. We compared different
oral prednisolone treatment patterns between cases and
controls by calculating odds ratios (ORs) with 95% CIs
using conditional logistic regression models. To control
for confounding, we computed multivariable odds ratios
(ORsadj) adjusting for the potential confounding
variables defined above.
Sensitivity analysis
We conducted a sensitivity analysis to assess whether
IRs, IRRs, and ORs (by current, recent, and past use of
prednisolone), change according to whether patients
were included in the cohorts at January 01 2000 (preva-
lent asthma patients) or thereafter (incident asthma
patients).
We conducted all analyses using SAS 9.4 software
(SAS Institute, Cary, NC), and we defined statistical
significance at the alpha-level of 0.05.
Results
Characteristics of the study population
Between 165,900 and 269,368 asthma patients were in-
cluded in each of the 11 cohorts, of whom between 836
and 16,192 developed an outcome of interest. The large
majority of case patients could be matched to at least 1
control for the nested case-control analyses. The mean
age of cases ranged from 40.8 years for affective disor-
ders to 72.7 years for cataract. Females were more fre-
quent among cases of all examined outcomes (Table 2).
A study flowchart and detailed characteristics of cases
and controls are provided in Additional file 2.
Cohort analyses
Compared with non-users, current users of oral prednis-
olone had statistically significantly increased crude IRRs
for all outcomes except glaucoma. The risk differences
between current and non-users of oral prednisolone
were greatest for severe infections (60.2/1000 person-
years), bone-related conditions (6.2/1000 person-years),
and chronic kidney disease (CKD, 5.5/1000 person-
years). The crude IRRs for ever users of oral prednisol-
one tended to be lower than the IRRs for current users
(reference: non-users), but remained statistically signifi-
cantly increased for most outcomes. For some outcomes
the IRRs were only minimally increased and effects
could be due to bias or confounding (Table 3).
Nested case-control analyses
After adjusting for potential confounding, current users
of oral prednisolone had statistically significantly in-
creased ORs of all investigated outcomes except ocular
diseases and hypertension, as compared with non-users
(Table 4).
Bloechliger et al. Respiratory Research  (2018) 19:75 Page 4 of 13
Ta
b
le
2
C
ha
ra
ct
er
is
tic
s
of
th
e
co
ho
rt
s
an
d
ca
se
s
fo
r
ea
ch
of
th
e
11
st
ud
y
ou
tc
om
es
Bo
ne
-r
el
at
ed
co
nd
iti
on
s
H
yp
er
te
ns
io
n
Pe
pt
ic
ul
ce
r
Se
ve
re
in
fe
ct
io
ns
H
er
pe
s
zo
st
er
D
M
2
C
at
ar
ac
t
G
la
uc
om
a
C
KD
A
ffe
ct
iv
e
di
so
rd
er
s
C
ar
di
ov
as
cu
la
r
ev
en
ts
C
oh
or
t
an
al
ys
is
In
di
vi
du
al
s
at
co
ho
rt
en
tr
y,
n
21
9,
17
4
22
3,
94
0
26
7,
56
9
24
4,
20
7
26
2,
84
7
26
2,
30
4
26
5,
96
4
26
9,
36
8
26
7,
13
8
16
5,
90
0
26
0,
99
5
In
di
vi
du
al
s
w
ith
co
ho
rt
en
tr
y
on
1
Ja
nu
ar
y
20
00
,n
40
,4
84
37
,2
50
46
,4
39
44
,6
21
46
,0
16
46
,0
46
46
,3
24
46
,8
92
47
,5
49
30
,7
22
44
,5
49
In
di
vi
du
al
s
w
ith
co
ho
rt
en
tr
y
af
te
r
1
Ja
nu
ar
y
20
00
,n
17
8,
69
0
18
6,
69
0
22
1,
13
0
19
9,
58
6
21
6,
83
1
21
6,
25
8
21
9,
64
0
22
2,
47
6
21
9,
58
9
13
5,
17
8
21
6,
44
6
C
as
es
,n
89
27
81
62
83
6
16
,1
92
41
75
51
95
53
56
14
73
88
25
49
65
40
28
To
ta
lf
ol
lo
w
-u
p
tim
e,
py
68
2,
39
8
65
3,
56
5
85
0,
87
4
74
4,
41
0
82
4,
68
9
82
0,
05
5
83
0,
28
9
85
4,
20
8
82
5,
10
8
52
5,
57
7
81
6,
95
9
N
es
te
d
ca
se
-c
on
tr
ol
an
al
ys
is
C
as
es
a ,
n
89
07
81
48
83
5
16
16
0b
27
48
c
41
63
51
89
53
27
14
67
87
78
49
62
40
14
C
on
tr
ol
s,
n
35
,4
45
32
,4
31
33
28
64
,3
16
b
10
83
9c
16
,6
05
20
,7
15
21
,0
19
58
32
34
,7
62
19
,8
09
15
,9
45
M
ea
n
ag
e
of
ca
se
s,
ye
ar
s
(S
D
)
54
.3
(+
/−
19
.6
)
58
.9
(+
/−
12
.9
)
63
.1
(+
/−
16
.7
)
51
.8
(+
/−
19
.7
)b
58
.6
(+
/−
20
.8
)c
57
.3
(+
/−
17
.5
)
58
.1
(+
/−
15
.3
)
72
.7
(+
/−
10
.9
)
68
.0
(+
/−
13
.0
)
71
.3
(+
/−
12
.0
)
40
.8
(+
/−
16
.7
)
67
.4
(+
/−
12
.4
)
Fe
m
al
es
am
on
g
ca
se
s,
%
69
.1
57
.4
60
.2
67
.7
b
64
.6
c
66
.0
60
.1
68
.9
62
.9
73
.1
62
.2
53
.0
A
bb
re
vi
at
io
ns
:C
KD
ch
ro
ni
c
ki
dn
ey
di
se
as
e,
D
M
2
di
ab
et
es
m
el
lit
us
ty
pe
2,
py
pe
rs
on
-y
ea
rs
,S
D
st
an
da
rd
de
vi
at
io
n
a C
as
es
fr
om
th
e
co
ho
rt
an
al
ys
is
th
at
co
ul
d
be
m
at
ch
ed
to
at
le
as
t
1
co
nt
ro
lo
n
th
e
in
de
x
da
te
,d
ur
at
io
n
of
fo
llo
w
-u
p
(+
/−
2
ye
ar
s)
,y
ea
r
of
bi
rt
h
(+
/−
2
ye
ar
s)
,s
ex
,a
nd
du
ra
tio
n
of
hi
st
or
y
on
th
e
da
ta
ba
se
(+
/−
0
ye
ar
s)
b
M
ai
n
an
al
ys
is
c S
en
si
tiv
ity
an
al
ys
is
re
st
ric
te
d
to
pa
tie
nt
s
w
ith
in
te
gr
at
ed
ho
sp
ita
le
pi
so
de
st
at
is
tic
s
lin
ka
ge
Bloechliger et al. Respiratory Research  (2018) 19:75 Page 5 of 13
Ta
b
le
3
C
ru
de
in
ci
de
nc
e
ra
te
s
an
d
in
ci
de
nc
e
ra
te
ra
tio
s
of
11
st
ud
y
ou
tc
om
es
am
on
g
as
th
m
a
pa
tie
nt
s,
st
ra
tif
ie
d
by
no
n-
us
e,
ev
er
us
e,
an
d
cu
rr
en
t
us
e
of
or
al
pr
ed
ni
so
lo
ne
U
se
of
or
al
pr
ed
ni
so
lo
ne
Bo
ne
-r
el
at
ed
co
nd
iti
on
s
H
yp
er
te
ns
io
n
Pe
pt
ic
ul
ce
r
Se
ve
re
in
fe
ct
io
ns
H
er
pe
s
zo
st
er
D
M
2
C
at
ar
ac
t
G
la
uc
om
a
C
KD
A
ffe
ct
iv
e
di
so
rd
er
s
C
ar
di
ov
as
cu
la
r
ev
en
ts
N
on
-u
se
(re
fe
re
nc
e)
C
as
es
,n
61
74
58
67
59
1
10
,1
15
28
82
35
34
36
39
10
57
60
34
36
02
28
68
Pe
rs
on
-y
ea
rs
50
9,
91
4
49
3,
64
6
63
1,
16
4
56
7,
25
4
61
4,
12
8
60
9,
90
3
61
8,
12
8
63
3,
40
4
61
6,
19
2
40
2,
78
2
60
7,
32
0
IR
/
10
00
pe
rs
on
-
ye
ar
s
(9
5%
C
I)
12
.1
(1
1.
8–
12
.4
)
11
.9
(1
1.
6–
12
.2
)
0.
9
(0
.9
–1
.0
)
17
.8
(1
7.
5–
18
.2
)
4.
7
(4
.5
–4
.9
)
5.
8
(5
.6
–6
.0
)
5.
9
(5
.7
–6
.1
)
1.
7
(1
.6
–1
.8
)
9.
8
(9
.5
–1
0.
0)
8.
9
(8
.7
–9
.2
)
4.
7
(4
.5
–4
.9
)
Ev
er
us
e
C
as
es
,n
27
53
22
95
24
5
60
77
12
93
16
61
17
17
41
6
27
91
13
63
11
60
Pe
rs
on
-y
ea
rs
17
2,
48
4
15
9,
91
9
21
9,
71
1
17
7,
15
6
21
0,
56
0
21
0,
15
2
21
2,
16
1
22
0,
80
4
20
8,
91
6
12
2,
79
6
20
9,
63
8
IR
/1
00
0
pe
rs
on
-y
ea
rs
(9
5%
C
I)
16
.0
(1
5.
4–
16
.6
)
14
.4
(1
3.
8–
14
.9
)
1.
1
(1
.0
–1
.3
)
34
.3
(3
3.
4–
35
.2
)
6.
1
(5
.8
–6
.5
)
7.
9
(7
.5
–8
.3
)
8.
1
(7
.7
–8
.5
)
1.
9
(1
.7
–2
.1
)
13
.4
(1
2.
9–
13
.9
)
11
.1
(1
0.
5–
11
.7
)
5.
5
(5
.2
–5
.9
)
IR
R
(9
5%
C
I)
1.
3
(1
.3
–1
.4
)
1.
2
(1
.2
–1
.3
)
1.
2
(1
.0
–1
.4
)
1.
9
(1
.9
–2
.0
)
1.
3
(1
.2
–1
.4
)
1.
4
(1
.3
–1
.4
)
1.
4
(1
.3
–1
.5
)
1.
1
(1
.0
–1
.3
)
1.
4
(1
.3
–1
.4
)
1.
2
(1
.2
–1
.3
)
1.
2
(1
.1
–1
.3
)
C
ur
re
nt
us
e
C
as
es
,n
53
3
45
1
51
22
68
25
7
39
8
27
2
62
54
1
26
9
23
6
Pe
rs
on
-y
ea
rs
29
,1
41
27
,0
32
36
,8
64
29
,0
74
35
,5
86
35
,4
68
35
,7
23
37
,1
25
35
,3
64
19
,8
03
35
,2
69
IR
/1
00
0
pe
rs
on
-y
ea
rs
(9
5%
C
I)
18
.3
(1
6.
7–
19
.8
)
16
.7
(1
5.
1–
18
.2
)
1.
4
(1
.0
–1
.8
)
78
.0
(7
4.
8–
81
.2
)
7.
2
(6
.3
–8
.1
)
11
.2
(1
0.
1–
12
.3
)
7.
6
(6
.7
–8
.5
)
1.
7
(1
.3
–2
.1
)
15
.3
(1
4.
0–
16
.6
)
13
.6
(1
2.
0–
15
.2
)
6.
7
(5
.8
–7
.5
)
IR
R
(9
5%
C
I)
1.
5
(1
.4
–1
.6
)
1.
4
(1
.3
–1
.5
)
1.
5
(1
.1
–2
.0
)
4.
4
(4
.2
–4
.6
)
1.
5
(1
.4
–1
.7
)
1.
9
(1
.7
–2
.2
)
1.
3
(1
.1
–1
.5
)
1.
0
(0
.8
–1
.3
)
1.
6
(1
.4
–1
.7
)
1.
5
(1
.3
–1
.7
)
1.
4
(1
.2
–1
.6
)
A
bb
re
vi
at
io
ns
:C
Ic
on
fid
en
ce
in
te
rv
al
,C
KD
ch
ro
ni
c
ki
dn
ey
di
se
as
e,
D
M
2
di
ab
et
es
m
el
lit
us
ty
pe
2,
IR
in
ci
de
nc
e
ra
te
,I
RR
in
ci
de
nc
e
ra
te
ra
tio
Bloechliger et al. Respiratory Research  (2018) 19:75 Page 6 of 13
Ta
b
le
4
O
dd
s
ra
tio
s
fo
r
th
e
11
st
ud
y
ou
tc
om
es
in
re
la
tio
n
to
or
al
pr
ed
ni
so
lo
ne
us
e
am
on
g
as
th
m
a
pa
tie
nt
s,
by
cu
rr
en
t,
re
ce
nt
or
pa
st
us
e
U
se
of
or
al
pr
ed
ni
so
lo
ne
Bo
ne
-r
el
at
ed
co
nd
iti
on
s
H
yp
er
te
ns
io
n
Pe
pt
ic
ul
ce
r
Se
ve
re
In
fe
ct
io
ns
a
H
er
pe
s
zo
st
er
D
M
2
C
at
ar
ac
t
G
la
uc
om
a
C
KD
A
ffe
ct
iv
e
di
so
rd
er
s
C
ar
di
ov
as
cu
la
r
ev
en
ts
N
o
us
e
(re
fe
re
nc
e)
C
as
es
,n
(%
)
45
58
(5
1.
2)
43
97
(5
4.
0)
41
6
(4
9.
8)
76
42
(4
7.
3)
20
56
(4
9.
4)
25
71
(4
9.
6)
25
82
(4
8.
5)
76
9
(5
2.
4)
43
44
(4
9.
5)
27
69
(5
5.
8)
20
96
(5
2.
2)
C
on
tr
ol
s,
n
(%
)
19
,0
38
(5
3.
7)
17
,8
02
(5
4.
9)
18
05
(5
4.
2)
36
,0
39
(5
6.
0)
88
75
(5
3.
5)
11
,0
71
(5
3.
4)
10
,6
41
(5
0.
6)
30
48
(5
2.
3)
17
,7
68
(5
1.
1)
12
,0
16
(6
0.
7)
88
27
(5
5.
4)
C
ur
re
nt
us
e
(<
18
0
d
be
fo
re
ID
)
C
as
es
,n
(%
)
84
6
(9
.5
)
65
4
(8
.0
)
80
(9
.6
)
22
27
(1
3.
8)
40
6
(9
.8
)
59
6
(1
1.
5)
43
3
(8
.1
)
11
9
(8
.1
)
81
1
(9
.2
)
43
4
(8
.8
)
37
9
(9
.4
)
C
on
tr
ol
s,
n
(%
)
26
14
(7
.4
)
24
14
(7
.4
)
22
5
(6
.8
)
44
89
(7
.0
)
13
07
(7
.9
)
16
17
(7
.8
)
16
12
(7
.7
)
46
3
(7
.9
)
27
63
(8
.0
)
12
10
(6
.1
)
11
38
(7
.1
)
O
R
cr
ud
e
(9
5%
C
I)
1.
36
(1
.2
6–
1.
47
)
1.
10
(1
.0
1–
1.
20
)
1.
57
(1
.2
3–
2.
01
)
2.
38
(2
.2
6–
2.
50
)
1.
36
(1
.2
2–
1.
52
)
1.
60
(1
.4
6–
1.
75
)
1.
11
(1
.0
0–
1.
23
)
1.
02
(0
.8
4–
1.
24
)
1.
21
(1
.1
2–
1.
30
)
1.
58
(1
.4
2–
1.
75
)
1.
41
(1
.2
6–
1.
58
)
O
R a
d
j
b
(9
5%
C
I)
1.
27
(1
.1
7–
1.
37
)
1.
03
(0
.9
4–
1.
12
)
1.
47
(1
.1
2–
1.
92
)
2.
16
(2
.0
5–
2.
27
)
1.
32
(1
.1
9–
1.
48
)
1.
35
(1
.2
2–
1.
49
)
1.
03
(0
.9
3–
1.
15
)
1.
06
(0
.8
7–
1.
29
)
1.
14
(1
.0
6–
1.
24
)
1.
47
(1
.3
2–
1.
63
)
1.
33
(1
.1
8–
1.
49
)
Re
ce
nt
us
e
(1
80
–3
65
d
be
fo
re
ID
)
C
as
es
,n
(%
)
51
9
(5
.8
)
40
5
(5
.0
)
50
(6
.0
)
11
21
(6
.9
)
26
7
(6
.4
)
29
3
(5
.7
)
31
0
(5
.8
)
75
(5
.1
)
47
8
(5
.5
)
30
8
(6
.2
)
21
2
(5
.3
)
C
on
tr
ol
s,
n
(%
)
18
58
(5
.2
)
16
08
(5
.0
)
15
9
(4
.8
)
30
87
(4
.8
)
88
9
(5
.4
)
10
36
(5
.0
)
11
02
(5
.2
)
29
7
(5
.1
)
18
50
(5
.3
)
87
1
(4
.4
)
76
5
(4
.8
)
O
R
cr
ud
e
(9
5%
C
I)
1.
18
(1
.0
8–
1.
29
)
1.
02
(0
.9
2–
1.
13
)
1.
36
(1
.0
1–
1.
83
)
1.
74
(1
.6
3–
1.
86
)
1.
32
(1
.1
6–
1.
50
)
1.
23
(1
.0
9–
1.
39
)
1.
17
(1
.0
4–
1.
31
)
0.
99
(0
.7
5–
1.
26
)
1.
06
(0
.9
7–
1.
17
)
1.
55
(1
.3
8–
1.
75
)
1.
18
(1
.0
3–
1.
37
)
O
R a
d
j
b
(9
5%
C
I)
1.
12
(1
.0
2–
1.
24
)
0.
95
(0
.8
5–
1.
05
)
1.
19
(0
.8
7–
1.
62
)
1.
59
(1
.4
9–
1.
70
)
1.
29
(1
.1
3–
1.
47
)
1.
05
(0
.9
2–
1.
19
)
1.
12
(0
.9
9–
1.
26
)
1.
00
(0
.7
9–
1.
28
)
1.
00
(0
.9
1–
1.
10
)
1.
49
(1
.3
2–
1.
69
)
1.
11
(0
.9
5–
1.
29
)
Pa
st
us
e
(>
36
5
d
be
fo
re
ID
)
C
as
es
,n
(%
)
29
84
(3
3.
5)
26
92
(3
3.
0)
28
9
(3
4.
6)
51
70
(3
2.
0
14
34
(3
4.
5)
17
29
(3
3.
3)
20
02
(3
7.
6)
50
4
(3
4.
4)
31
45
(3
5.
8)
14
51
(2
9.
2)
13
27
(3
3.
1)
C
on
tr
ol
s,
n
(%
)
11
,9
35
(3
3.
7)
10
,6
07
(3
2.
7)
11
39
(3
4.
2)
20
,7
01
(3
2.
2)
55
34
(3
3.
3)
69
91
(3
3.
8)
76
64
(3
6.
5)
20
24
(3
4.
7)
12
,3
81
(3
5.
6)
57
12
(2
8.
8)
52
15
(3
2.
7)
O
R
cr
ud
e
(9
5%
C
I)
1.
05
(1
.0
0–
1.
10
)
1.
03
(0
.9
8–
1.
08
)
1.
11
(0
.9
5–
1.
30
)
1.
20
(1
.1
6–
1.
25
)
1.
13
(1
.0
5–
1.
21
)
1.
08
(1
.0
1–
1.
15
)
1.
08
(1
.0
2–
1.
15
)
0.
99
(0
.8
8–
1.
11
)
1.
04
(0
.9
9–
1.
09
)
1.
12
(1
.0
5–
1.
19
)
1.
08
(1
.0
1–
1.
16
)
O
R a
d
j
b
(9
5%
C
I)
1.
03
(0
.9
8–
1.
08
)
0.
97
(0
.9
2–
1.
02
)
1.
05
(0
.8
9–
1.
25
)
1.
14
(1
.1
0–
1.
19
)
1.
13
(1
.0
5–
1.
21
)
0.
98
(0
.9
2–
1.
05
)
1.
04
(0
.9
8–
1.
10
)
1.
00
(0
.8
9–
1.
13
)
1.
01
(0
.9
7–
1.
07
)
1.
10
(1
.0
2–
1.
18
)
1.
06
(0
.9
8–
1.
14
)
A
bb
re
vi
at
io
ns
:C
Ic
on
fid
en
ce
in
te
rv
al
,C
KD
ch
ro
ni
c
ki
dn
ey
di
se
as
e,
d
da
ys
,D
M
2
di
ab
et
es
m
el
lit
us
ty
pe
2,
ID
in
de
x
da
te
,O
R a
d
j
ad
ju
st
ed
od
ds
ra
tio
a R
es
ul
ts
fr
om
m
ai
n
an
al
ys
is
(t
he
se
ns
iti
vi
ty
an
al
ys
is
re
st
ric
te
d
to
pa
tie
nt
s
w
ith
in
te
gr
at
ed
ho
sp
ita
le
pi
so
de
st
at
is
tic
s
yi
el
de
d
si
m
ila
r
re
su
lts
,d
at
a
no
t
sh
ow
n)
b
A
dj
us
te
d
fo
r
al
co
ho
lc
on
su
m
pt
io
n,
sm
ok
in
g
st
at
us
,b
od
y
m
as
s
in
de
x,
cu
rr
en
t
or
pa
st
us
e
of
in
ha
le
d
br
on
ch
od
ila
to
rs
,n
on
st
er
oi
da
la
nt
i-i
nf
la
m
m
at
or
y
dr
ug
s,
pl
at
el
et
ag
gr
eg
at
io
n
in
hi
bi
to
rs
,a
nt
ic
oa
gu
la
nt
s,
pr
ot
on
pu
m
p
in
hi
bi
to
rs
,v
ita
m
in
D
/c
al
ci
um
,b
is
ph
os
ph
on
at
es
,i
m
m
un
os
up
pr
es
sa
nt
s,
nu
m
be
r
of
pr
es
cr
ip
tio
ns
of
in
ha
le
d
co
rt
ic
os
te
ro
id
s,
an
d
C
ha
rls
on
C
om
or
bi
di
ty
In
de
x
Bloechliger et al. Respiratory Research  (2018) 19:75 Page 7 of 13
Severe infection was the only outcome with a substan-
tially increased OR (2.16). Peptic ulcer (OR = 1.47) and
affective disorders (OR = 1.47) had smaller increases in
risk, and several other outcomes had marginally in-
creased risks (herpes zoster, cardiovascular events, dia-
betes mellitus type 2 [DM2], and bone related
conditions). Cataract was associated with an increase in
risk at cumulative doses > 2000 mg, average daily doses
> 5 mg/day, or ≥4 prescriptions/year (ORs = 1.43, 3.29,
and 1.80, respectively), but not at lower doses (Figs. 1, 2
and 3). Hypertension, glaucoma, and CKD were not as-
sociated with current use of oral prednisolone (Table 4).
Recent users had small increases in risk of severe
infections, affective disorders, and herpes zoster, but not
of other outcomes. There were no elevated risks among
past users (Table 4).
Figures 1, 2 and 3 display the results of the sub-
analyses among current users of oral prednisolone by
cumulative dose before the index date, average daily
dose within 2 years before the index date (the figures for
the average daily dose prescribed ever, within 1 year, or
within 5 years before the index date pointed in the same
direction and are not shown), and frequency of use. Pos-
sible dose response-relationships were observed for
bone-related conditions, severe infections, cataract,
affective disorders, DM2, and cardiovascular events. For
OR adj. (95% CI)Outcome Patients, n
Bone-related conditions
<500 mg
500-2000 mg
>2000 mg
Hypertension
<500 mg
500-2000 mg
>2000 mg
Peptic ulcer
<500 mg
500-2000 mg
>2000 mg
Severe infections*
<500 mg
500-2000 mg
>2000 mg
Herpes zoster
<500 mg
500-2000 mg
>2000 mg
Diabetes mellitus type 2
<500 mg
500-2000 mg
>2000 mg
Cataract
<500 mg
500-2000 mg
>2000 mg
Glaucoma
<500 mg
500-2000 mg
>2000 mg
Chronic kidney disease
<500 mg
500-2000 mg
>2000 mg
Affective disorders
<500 mg
500-2000 mg
>2000 mg
Cardiovascular events
<500 mg
500-2000 mg
>2000 mg
1539
1429
492
1389
1278
401
135
131
39
3201
2700
815
761
686
266
928
940
345
795
866
384
245
248
89
1468
1574
532
903
582
159
670
641
206
0.5 1 1.5 2 2.5 3 3.5
Fig. 1 Current use of oral prednisolone and the risk of 11 study outcomes among asthma patients, by cumulative dose ever prescribed before
the index date. Abbreviations: ORadj, adjusted odds ratio; CI, confidence interval. *Results from main analysis (the sensitivity analysis restricted to
patients with integrated hospital episode statistics yielded similar results, data not shown). Odds ratios are presented on a logarithmic scale and were
adjusted for alcohol consumption, smoking status, body mass index, current or past use of inhaled bronchodilators, nonsteroidal anti-inflammatory
drugs, platelet aggregation inhibitors, anticoagulants, proton pump inhibitors, vitamin D/calcium, bisphosphonates, immunosuppressants, number of
prescriptions of inhaled corticosteroids (as a continuous variable), and Charlson Comorbidity Index (as a continuous variable)
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herpes zoster and peptic ulcer, no dose-response rela-
tionships were observed.
The results of the sensitivity analysis were not consid-
erably different between prevalent or incident asthma
patients (data not shown).
Discussion
In this large observational study based on CPRD data,
oral prednisolone use was associated with the occur-
rence of various incident diseases in adult patients with
asthma. This association was strongest in current users
of oral prednisolone, and gradually declined in recent or
past users, compared with non-users. There was a strong
association with current use of oral prednisolone and
severe infections and possible dose response relation-
ships with bone-related conditions, cataract, DM2,
affective disorders, and cardiovascular events. There was
also a small non-dose dependent association with herpes
zoster and peptic ulcer. In contrast, oral prednisolone
use was not associated with the risk of glaucoma, CKD,
or hypertension, irrespective of timing of use or the
prescribed dose.
The ORs of all outcomes associated with current oral
prednisolone use, except cataract, were also increased in
OR adj. (95% CI)Outcome Patients, n
Bone-related conditions
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Hypertension
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Peptic ulcer
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Severe infections*
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Herpes zoster
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Diabetes mellitus type 2
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Cataract
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Glaucoma
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Chronic kidney disease
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Affective disorders
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
Cardiovascular events
<=1 mg/d
>1 mg/d-5 mg/d
>5 mg/d
2735
639
86
2434
555
79
236
65
5362
1216
138
1351
317
45
1718
433
62
1516
462
67
453
117
12
2775
706
93
1379
236
29
1199
290
28
0.2 0.5 1 1.5 2 3 4 5 6
Fig. 2 Current use of oral prednisolone and the risk of 11 study outcomes among asthma patients, by the average daily dose prescribed within
2 years before the index date. Abbreviations: ORadj, adjusted odds ratio; CI, confidence interval.
† Cells contain < 5 patients, owing to ethics
regulations to preserve confidentiality, odds ratios are not displayed. *Results from main analysis (the sensitivity analysis restricted to patients with
integrated hospital episode statistics yielded similar results, data not shown). Odds ratios are presented on a logarithmic scale and were adjusted
for alcohol consumption, smoking status, body mass index, current or past use of inhaled bronchodilators, nonsteroidal anti-inflammatory drugs,
platelet aggregation inhibitors, anticoagulants, proton pump inhibitors, vitamin D/calcium, bisphosphonates, immunosuppressants, number of
prescriptions of inhaled corticosteroids (as a continuous variable), and Charlson Comorbidity Index (as a continuous variable)
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OR adj. (95% CI)Outcome Patients, n
Bone-related conditions
Low use
Medium use
High use
Hypertension
Low use
Medium use
High use
Peptic ulcer
Low use
Medium use
High use
Severe infections*
Low use
Medium use
High use
Herpes zoster
Low use
Medium use
High use
Diabetes mellitus type 2
Low use
Medium use
High use
Cataract
Low use
Medium use
High use
Glaucoma
Low use
Medium use
High use
Chronic kidney disease
Low use
Medium use
High use
Affective disorders
Low use
Medium use
High use
Cardiovascular events
Low use
Medium use
High use
2432
827
201
2165
743
160
225
64
16
4837
1544
335
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417
106
1574
509
130
1402
506
137
409
151
22
2488
861
225
1206
368
70
1044
373
100
0.5 1 1.5 2 3 4 5
Fig. 3 (See legend on next page.)
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patients who had only received an average of 1 prescrip-
tion per year, a cumulative dose < 500 mg, and/or an
average daily dose ≤1 mg within 2 years before the index
date. As we did not observe increased ORs in patients
with past use of these intermittent and low dose
regimens, mere confounding by generally poorer health
of prednisolone users compared with non-users is
unlikely. Furthermore, cataract, a slowly progressive
disease which is associated with frailty and overall
disease burden [20], was only associated with the highest
level of exposure for all categories of use: highest
cumulative and daily dose and most frequent oral pred-
nisolone regimens.
Previous studies that assessed OCS-related adverse
events among asthma patients found similarly increased
risk estimates of bone-related, gastrointestinal, infectious,
metabolic, renal, psychiatric, and cardiovascular complica-
tions in association with OCS use [10–14]. In accordance
with our results, previous studies did not find an associ-
ation between OCS exposure and the occurrence of
glaucoma in asthma patients [10, 11, 14] which is also
consistent with findings from studies of non-asthmatic
OCS users [21, 22]. As previously demonstrated, the risk
of cataract in association with OCS use appears to
increase notably after long treatment duration or at high
cumulative doses or frequency of use [14, 23, 24].
Previous studies among asthma patients found a statis-
tically significant association between OCS use and
hypertension [10–12, 14] while we observed no such
association after adjusting for confounding. This discrep-
ancy might be explained by our stricter definition of
hypertension which required patients to receive antihy-
pertensive treatment in addition to a hypertension
diagnosis, whereas in all other studies, patients only
needed to have a hypertension diagnosis.
Although dose-response relationships between OCS
use and various adverse events have been previously
reported [6, 7, 12, 23–25], some of which among US
populations of patients with asthma [12–14], this
comprehensive longitudinal study adds evidence from
the UK, based on one of the largest and best validated
medical records database worldwide. This is the first
study providing absolute and relative frequencies of
potential corticosteroid-related complications among pa-
tients with asthma who used or did not use OCS,
whereas previous studies reported relative frequencies
only [12–14]. While previous cohort studies either clas-
sified OCS exposure based on cumulative dose [12, 13]
or on the frequency of OCS prescriptions issued per year
[14], the results of our study provide evidence that no
matter which of these exposure classification approaches
is taken, observed associations between the intensity of
OCS use and related adverse events remain stable.
Despite these strengths, there are limitations to our
study. As in all electronic database studies, our prednisol-
one exposure definition was based on issued prescriptions
and not on actual medication intake. The calculated
cumulative dose represents the cumulative dose ever
prescribed rather than ingested OCS; e.g. the observed as-
sociations between oral prednisolone use and investigated
outcomes were more likely to be under- rather than
overestimated. Additionally, we had some missing data on
quantity of tablets and dosage instructions necessary to
calculate current and past use periods in the cohort
studies. Although diagnoses are well validated in the
CPRD, we cannot rule out the possibility of coding errors.
To avoid including false positive outcomes, we based our
definitions of most outcomes not only on Read codes, but
also on recorded prescriptions or procedures for these
specific disorders. However, missing diagnoses could have
been an issue particularly for the outcomes peptic ulcer (es-
pecially types without haemorrhage) or bone-related condi-
tions (especially osteoporosis without bone-fractures), as
these outcomes may have gone unnoticed by the GP. This
type of misclassification could have biased our results
towards the null hypothesis if it was not differential across
users and non-users of prednisolone, or, if users of prednis-
olone were more closely observed with regard to these
outcomes, the risk estimates could have been overesti-
mated. While we could distinguish between more or
less frequent average use of oral prednisolone, we
could not classify patients into continuous or burst users,
as available dosage instructions were not detailed enough.
Furthermore, it was not possible to disentangle potential
effects of oral prednisolone from an underlying effect of
asthma severity, as more severe asthma patients by
definition are more likely to be prescribed oral prednisol-
one. Previous studies have demonstrated that asthma
patients have a higher prevalence of metabolic, cardiovas-
cular, and psychiatric diseases, compared with the general
(See figure on previous page.)
Fig. 3 Current use of oral prednisolone and the risk of 11 study outcomes among asthma patients, by frequency of use before the index date
(low use: on average 1 prescription/year; medium use: on average 2–3 prescriptions/year; high use: on average≥ 4 prescriptions/year).
Abbreviations: ORadj, adjusted odds ratio; CI, confidence interval. *Results from main analysis (the sensitivity analysis restricted to patients with
integrated hospital episode statistics yielded similar results, data not shown). Odds ratios are presented on a logarithmic scale and were adjusted
for alcohol consumption, smoking status, body mass index, current or past use of inhaled bronchodilators, nonsteroidal anti-inflammatory drugs,
platelet aggregation inhibitors, anticoagulants, proton pump inhibitors, vitamin D/calcium, bisphosphonates, immunosuppressants, number of
prescriptions of inhaled corticosteroids (as a continuous variable), and Charlson Comorbidity Index (as a continuous variable)
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population [26–28]. These associations are more likely to
be bi- than unidirectional, and supposedly based on
common pathophysiological parameters of these diseases
[26–28]. We are however not aware of studies reporting a
higher prevalence of these comorbidities in patients with
severe asthma compared with less severe asthma, and
confounding by asthma severity for these outcomes was
unlikely in this study, as we observed no association
between current oral prednisolone use and hypertension,
or between past use of oral prednisolone and cardiovascu-
lar events, DM2, or affective disorders. We did not adjust
our analyses for multiple comparisons because all analyses
were planned in advance and based on an a priori
hypothesis [29, 30].
Conclusion
In conclusion, this study adds evidence from the UK that
new use of oral prednisolone is associated with an in-
creased risk of various incident diseases. Some outcomes
were associated with not only high dose and frequent
oral prednisolone use, but also with low dose and inter-
mittent regimens. A possible dose-response relationship
was observed for bone-related conditions, severe infec-
tions, cataract, affective disorders, DM2, and cardiovas-
cular events. Our results support the need of developing
new treatments for severe asthma with a better safety
profile than that of OCS.
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